NeoLAB® Solid Tumor Liquid Biopsy
Use
NeoLAB® Solid Tumor Liquid Biopsy is a highly sensitive next-generation sequencing (NGS)‐based liquid biopsy panel designed for genomic profiling of solid tumors when tissue biopsies may not be feasible. It analyzes circulating cell‑free DNA to detect clinically relevant single nucleotide variants (SNVs) and insertions/deletions (indels) across a panel of genes associated with solid tumor oncogenesis, facilitating therapy selection, prognosis, and monitoring of tumor molecular landscape.
Special Instructions
Note: This test has been discontinued and replaced by the enhanced NEO PanTracer LBx. Ordering is no longer supported. Specimen requirements: peripheral blood—two 10 mL Streck Cell‑Free DNA BCT® tubes. Transport using cold packs, ensuring that cold packs do not contact the specimen directly.
Limitations
As a cfDNA liquid biopsy, performance may be influenced by tumor shedding levels; low circulating tumor DNA may limit detection sensitivity. Discontinued status indicates that this test is superseded by NEO PanTracer LBx, so clients should transition to the newer offering for continued service. Clinical interpretation may be limited by small gene panel and lack of copy number, fusion, MSI, or TMB assessment that are available in newer panels.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
two 10 mL Streck Cell‑Free DNA BCT® tubes
Minimum Volume
Not provided
Container
Streck Cell‑Free DNA BCT® tubes
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.